Researchers at Stanford have developed constitutively active, programmable synthetic cytokine receptors capable of polarizing human macrophages to a variety of user-defined cell states which may be useful for therapeutic applications.
The limited duration of humoral responses to vaccination is a key issue in the fight against infectious diseases, as antibody levels wane over time, leaving individuals vulnerable to reinfection.
Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Stanford researchers have proposed antibody-based reduction of Neuromedin (NMU) signaling as a therapeutic strategy to improve glucose metabolism in multiple physiological or disease states, including obesity, diabetes, and cancer where NMU levels are elevated.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
Hydrogel-based tissue engineering scaffolds are widely used for culturing cells in three dimensions (3D) due to their tissue-like water content, tunable biochemical and physical properties, and ease of cell encapsulation and distribution in 3D.